Lisocabtagene Maraleucel (liso-cel) in Patients (Pt) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001

We report outcomes from prespecified subgroup analyses based on high-risk features from the MCL cohort of TRANSCEND NHL 001 (NCT02631044) of liso-cel in pts with R/R MCL.

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: M. Lia Palomba, Tanya Siddiqi, Leo I. Gordon, Manali Kamdar, Matthew Lunning, Alexandre V Hirayama, Jeremy S. Abramson, Jon Arnason, Nilanjan Ghosh, Amitkumar Mehta, Charalambos Andreadis, Scott R. Solomon, Ana Kostic, Ashvin Singh, Ricardo Espinola, Lily Tags: 17 Source Type: research